Citigroup Maintains Buy on Apellis Pharmaceuticals, Raises Price Target to $54
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Yigal Nochomovitz maintains a 'Buy' rating on Apellis Pharmaceuticals and raises the price target from $45 to $54.
August 30, 2023 | 6:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Citigroup maintains a 'Buy' rating on Apellis Pharmaceuticals and raises the price target from $45 to $54, indicating positive sentiment towards the stock.
The raised price target by Citigroup indicates a positive outlook for Apellis Pharmaceuticals. This could lead to increased investor confidence and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100